secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001005286-25-000146
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M
--------------------------------------------------------------------------------

- Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.
- Net loss narrowed to $10.0M ($0.29 loss per share) from $16.2M ($0.53) a year ago.
- Adjusted EBITDA of $3.1M vs negative $1.8M in prior year; SG&A down $5.9M.
- Affirms transition period guidance: revenue $74-76M, Adjusted EBITDA $12-14M.
- Signed 4 new programs (2 post-quarter); commercial site transfer with large pharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/0001005286-25-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/lndc-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001005286-25-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer